PhRMA Continues Push For Medicare Part D Redesign In Drug Pricing Legislation
Executive Summary
PhRMA exec discusses industry's opposition to generic mandates in formularies, its continued hope for rebate reform, and the damage Pelosi's bill could spawn even if it fails.
You may also be interested in...
Half Of 1st Approved Generics Do Not Launch Due To Part D Formulary Obstacles, AAM Says
Medicare Part D program should place generics on tiers separate from brand drugs and create a dedicated tier for specialty generics and biosimilars, AAM advocates in white paper.
Part D Out-Of-Pocket Cap Would Be $2,000 In House Drug Pricing Bill
It may seem perverse to look for silver linings for the drug industry in the House leaderships “price negotiation” bill. But if you can get past Title 1, the bill reads like an attempt to negotiate with the Senate Finance Committee – and it’s not all bad.
House Democrats Launch Price Negotiation Push: Extreme Plan Assures Strong Opposition
Pelosi is moving forward with a draconian plan to limit US prices to an international benchmark. For now, the “bill” is a three-page outline subject to considerable legislative drafting – and so extreme as to rule out bipartisan compromise for the time being.